Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

BioAtla (NASDAQ:BCAB – Get Free Report) is anticipated to announce its quarterly earnings results after the market closes on ...

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell ...

Angle updates on AstraZeneca development work and Eisai’s phase 2 pilot study: London Tuesday, March 25, 2025, 11:00 Hrs [IST] Angle Inc, a world-leading liquid biopsy company w ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.